Ionis Pharmaceuticals Fell 45% With The Case Still Split

The past few months have been brutal for Ionis Pharmaceuticals holders. FDA approval of Tryngolza for severe hypertriglyceridemia, complete with blockbuster sales projections and a sharp after-hours pop, looked like the kind of win long-term bulls had been waiting for. Holding Ionis Pharmaceuticals from the start of the year would have meant a 45.3% loss, including dividends. If you had been weighing a position on 1 January, how much of that risk was already visible in the story then?

The move put Ionis Pharmaceuticals in the middle of this trade. Scan 35 healthcare AI stocks for other companies exposed to it.

The Two Ionis Pharmaceuticals Stories Investors Had To Weigh

The shares cost US$79.11 at the start, and Ionis Pharmaceuticals sat between two very different but plausible stories about what its platform could deliver.

In the bullish script, a Fair Value of US$96, essentially the price implied if everything in that scenario played out, rested on rapid 27.7% revenue growth and a shift from a current loss to a 19.0% profit margin within about three years.

The more cautious view pointed to a Fair Value of US$69.48, built on 17.3% revenue growth assumptions but flagged pressure from lower pricing as Olezarsen moved into broader severe hypertriglyceridemia use.

What The Results Changed In The Ionis Pharmaceuticals Story

Ionis Pharmaceuticals secured FDA approval for Tryngolza in severe hypertriglyceridemia, which supported the optimistic case that its RNA platform could extend into larger indications. The same period brought a harsh reality check. Q2 2026 revenue was US$267.949 million versus US$452.049 million in Q2 2025, with a net margin moving from 27.3% to a loss at 42.8%. The evidence pointed in both directions.

The lesson is about which forecast to test first. For a business like Ionis Pharmaceuticals, it may be useful to track whether expanding labels and new launches show up in sustained revenue and margin progress, rather than focusing only on approvals and pipeline headlines.

What You Are Really Paying For In Ionis Pharmaceuticals Today

Ionis Pharmaceuticals now trades at US$43.54, well below where the year started. The selected Narrative sees Fair Value above that level, resting on execution in severe hypertriglyceridemia and a broader commercial shift rather than reliance on any single trial headline.

On that view, a buyer today is effectively assuming that Tryngolza and other key launches turn into sustained, high quality revenue that supports better margins and justifies more of the current pipeline spend.

"Expanding into larger patient populations and strong physician acceptance position Ionis for substantial market share gains and sustained top-line growth. Strategic partnerships, growing royalties, and a competitive edge in rare disease commercialization enhance financial resilience and support margin expansion."

That disagreement has a full argument behind it. → Uncover the higher Fair Value this Narrative argues for

Go Straight To The Source

This company's disappointment is already part of the story. Your next idea could come from looking where the price and the possibilities still seem far apart. Here are three companies priced below our estimates.

• Company 1 - 48% below our estimate - supplies steel reinforcement as long term public infrastructure programs translate commitments into demand.
• Company 2 - 44% below our estimate - expands aviation aftermarket presence as acquisitions increase repair capacity and deepen parts distribution.
• Company 3 - 49% below our estimate - builds network and energy infrastructure aligned with extended utility, pipeline and data center plans.

Those are three of them. See every one of the 31 undervalued companies on it →

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com